Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$181.94
3.912.20%
al cierre: -
$181.94
0.000.00%
After hour: 4:33 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Tenet Healthcare Corp ha un obiettivo di prezzo di consenso pari a $165.32, stabilito in base alle ultime valutazioni degli analisti di 26. Le ultime 3 valutazioni degli analisti sono state rilasciate da Wells Fargo, JP Morgan y Baird il agosto 14, 2025, agosto 4, 2025 y julio 25, 2025. Con un obiettivo di prezzo medio di $189 tra le Wells Fargo, JP Morgan y Baird, c'è un implicito 3.88% upside per Tenet Healthcare Corp da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Wells Fargo
JP Morgan
Baird
Barclays
UBS
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Tenet Healthcare
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/14/2025 | 9.93% | Wells Fargo | $195 → $200 | Maintains | Overweight | |||
08/04/2025 | 9.93% | JP Morgan | $190 → $200 | Maintains | Overweight | |||
07/28/2025 | — | Wolfe Research | — | Downgrade | Outperform → Peer Perform | |||
07/25/2025 | -8.21% | Baird | $195 → $167 | Maintains | Neutral | |||
07/24/2025 | 14.32% | Barclays | $215 → $208 | Maintains | Overweight | |||
07/23/2025 | 30.81% | UBS | $230 → $238 | Maintains | Buy | |||
07/23/2025 | 9.93% | Raymond James | $185 → $200 | Reiterates | Outperform → Outperform | |||
07/23/2025 | 3.33% | Guggenheim | $180 → $188 | Maintains | Buy | |||
07/16/2025 | 12.67% | Truist Securities | $190 → $205 | Maintains | Buy | |||
07/11/2025 | 6.63% | Mizuho | $184 → $194 | Maintains | Outperform | |||
06/09/2025 | 15.42% | Morgan Stanley | $175 → $210 | Maintains | Overweight | |||
06/02/2025 | 18.17% | Barclays | $171 → $215 | Maintains | Overweight | |||
05/29/2025 | 7.18% | Wells Fargo | $150 → $195 | Upgrade | Equal-Weight → Overweight | |||
05/14/2025 | -1.07% | B of A Securities | $165 → $180 | Maintains | Buy | |||
05/12/2025 | 4.43% | Truist Securities | $175 → $190 | Maintains | Buy | |||
05/05/2025 | -15.36% | Goldman Sachs | $134 → $154 | Maintains | Neutral | |||
05/05/2025 | -3.81% | Morgan Stanley | $165 → $175 | Maintains | Overweight | |||
04/30/2025 | -6.01% | Barclays | $161 → $171 | Maintains | Overweight | |||
04/30/2025 | 3.88% | RBC Capital | $183 → $189 | Maintains | Outperform | |||
04/30/2025 | 26.42% | UBS | $217 → $230 | Maintains | Buy | |||
04/15/2025 | -24.7% | Baird | $153 → $137 | Downgrade | Outperform → Neutral | |||
04/09/2025 | -9.31% | Guggenheim | → $165 | Initiates | → Buy | |||
03/26/2025 | -9.31% | Morgan Stanley | → $165 | Initiates | → Overweight | |||
02/13/2025 | -2.72% | Cantor Fitzgerald | $177 → $177 | Reiterates | Overweight → Overweight | |||
02/13/2025 | -11.51% | Barclays | $190 → $161 | Maintains | Overweight | |||
01/07/2025 | 1.68% | Keybanc | $200 → $185 | Maintains | Overweight | |||
01/06/2025 | -3.81% | Truist Securities | $190 → $175 | Maintains | Buy | |||
12/17/2024 | -3.81% | JP Morgan | → $175 | Assumes | → Overweight | |||
12/16/2024 | -23.05% | Goldman Sachs | $196 → $140 | Downgrade | Buy → Neutral | |||
11/25/2024 | -17.56% | Wells Fargo | $205 → $150 | Downgrade | Overweight → Equal-Weight | |||
11/22/2024 | 7.18% | Raymond James | $195 → $195 | Downgrade | Strong Buy → Outperform | |||
11/08/2024 | 4.43% | Barclays | $171 → $190 | Maintains | Overweight | |||
11/06/2024 | 12.67% | Wells Fargo | $195 → $205 | Maintains | Overweight | |||
10/30/2024 | -2.72% | Cantor Fitzgerald | $168 → $177 | Maintains | Overweight | |||
10/30/2024 | 7.73% | Goldman Sachs | $173 → $196 | Maintains | Buy | |||
10/30/2024 | 0.58% | RBC Capital | $174 → $183 | Maintains | Outperform | |||
10/30/2024 | 4.43% | Truist Securities | $180 → $190 | Reiterates | Buy → Buy | |||
10/30/2024 | 19.27% | UBS | $197 → $217 | Maintains | Buy | |||
10/22/2024 | 7.18% | Wells Fargo | $175 → $195 | Maintains | Overweight | |||
10/14/2024 | -1.07% | Truist Securities | $170 → $180 | Maintains | Buy | |||
10/11/2024 | 9.93% | Keybanc | → $200 | Initiates | → Overweight | |||
10/04/2024 | -7.66% | Cantor Fitzgerald | $168 → $168 | Reiterates | Overweight → Overweight | |||
10/01/2024 | -7.66% | Cantor Fitzgerald | $168 → $168 | Reiterates | Overweight → Overweight | |||
08/20/2024 | -7.66% | Cantor Fitzgerald | $168 → $168 | Reiterates | Overweight → Overweight | |||
08/19/2024 | -7.66% | Cantor Fitzgerald | $168 → $168 | Reiterates | Overweight → Overweight | |||
08/14/2024 | 8.28% | UBS | $180 → $197 | Maintains | Buy | |||
07/30/2024 | -4.91% | Goldman Sachs | $156 → $173 | Maintains | Buy | |||
07/30/2024 | -3.81% | Wells Fargo | $145 → $175 | Maintains | Overweight | |||
07/29/2024 | -6.01% | Barclays | $156 → $171 | Maintains | Overweight | |||
07/25/2024 | -6.01% | Citigroup | $139 → $171 | Maintains | Buy | |||
07/25/2024 | -3.81% | Raymond James | $130 → $175 | Maintains | Strong Buy | |||
07/25/2024 | -6.56% | Truist Securities | $155 → $170 | Reiterates | Buy → Buy | |||
07/25/2024 | -7.66% | Cantor Fitzgerald | $112 → $168 | Maintains | Overweight | |||
07/15/2024 | -14.81% | Truist Securities | $130 → $155 | Maintains | Buy | |||
07/10/2024 | -14.26% | Barclays | $147 → $156 | Maintains | Overweight | |||
07/10/2024 | -38.44% | Cantor Fitzgerald | $112 → $112 | Reiterates | Overweight → Overweight | |||
07/09/2024 | -38.44% | Cantor Fitzgerald | $112 → $112 | Reiterates | Overweight → Overweight | |||
07/02/2024 | -38.44% | Cantor Fitzgerald | $112 → $112 | Reiterates | Overweight → Overweight | |||
06/28/2024 | -14.81% | Deutsche Bank | $150 → $155 | Maintains | Buy | |||
05/30/2024 | -23.05% | JP Morgan | $107 → $140 | Maintains | Overweight | |||
05/30/2024 | -17.56% | Deutsche Bank | $126 → $150 | Maintains | Buy | |||
05/30/2024 | -15.91% | Baird | → $153 | Initiates | → Outperform | |||
05/02/2024 | -19.2% | Barclays | $113 → $147 | Maintains | Overweight | |||
05/01/2024 | -32.94% | Stephens & Co. | $95 → $122 | Maintains | Equal-Weight | |||
05/01/2024 | -25.25% | RBC Capital | $109 → $136 | Maintains | Outperform | |||
05/01/2024 | -17.56% | UBS | $137 → $150 | Maintains | Buy | |||
05/01/2024 | -28.55% | Mizuho | $118 → $130 | Reiterates | Buy → Buy | |||
05/01/2024 | -28.55% | Truist Securities | $120 → $130 | Reiterates | Buy → Buy | |||
04/12/2024 | -30.75% | Deutsche Bank | $100 → $126 | Maintains | Buy | |||
04/10/2024 | -42.84% | Cantor Fitzgerald | $104 → $104 | Reiterates | Overweight → Overweight | |||
03/28/2024 | -36.79% | Wells Fargo | $105 → $115 | Maintains | Overweight | |||
03/27/2024 | -32.94% | Wolfe Research | → $122 | Upgrade | Peer Perform → Outperform | |||
03/11/2024 | -39.54% | Mizuho | $100 → $110 | Maintains | Buy | |||
03/06/2024 | -37.89% | Barclays | → $113 | Initiates | → Overweight | |||
03/05/2024 | -42.84% | Cantor Fitzgerald | $104 → $104 | Reiterates | Overweight → Overweight | |||
02/15/2024 | -42.29% | Wells Fargo | $98 → $105 | Maintains | Overweight | |||
02/09/2024 | -42.29% | Truist Securities | $92 → $105 | Maintains | Buy | |||
02/09/2024 | -40.09% | RBC Capital | $97 → $109 | Maintains | Outperform | |||
02/09/2024 | -45.04% | Mizuho | $90 → $100 | Maintains | Buy | |||
02/09/2024 | -42.84% | Cantor Fitzgerald | $94 → $104 | Maintains | Overweight | |||
11/20/2023 | -49.43% | Truist Securities | → $92 | Reiterates | Buy → Buy | |||
11/17/2023 | -55.48% | JP Morgan | $91 → $81 | Maintains | Overweight | |||
11/14/2023 | -53.28% | Jefferies | $95 → $85 | Maintains | Buy | |||
11/09/2023 | -53.28% | Goldman Sachs | $98 → $85 | Maintains | Buy | |||
11/02/2023 | -48.33% | UBS | $104 → $94 | Maintains | Buy | |||
11/01/2023 | -50.53% | Raymond James | $95 → $90 | Maintains | Strong Buy | |||
10/31/2023 | -57.68% | Mizuho | $94 → $77 | Maintains | Buy | |||
10/31/2023 | -60.43% | RBC Capital | $87 → $72 | Maintains | Outperform | |||
10/20/2023 | -60.98% | Wells Fargo | $83 → $71 | Maintains | Overweight | |||
09/14/2023 | -48.33% | Cantor Fitzgerald | $76 → $94 | Maintains | Overweight | |||
08/14/2023 | -46.14% | Goldman Sachs | $89 → $98 | Maintains | Buy | |||
08/02/2023 | -46.14% | Credit Suisse | $92 → $98 | Maintains | Outperform | |||
08/02/2023 | -47.78% | Raymond James | $85 → $95 | Maintains | Strong Buy | |||
08/01/2023 | -42.84% | UBS | $95 → $104 | Maintains | Buy | |||
08/01/2023 | -52.18% | RBC Capital | $84 → $87 | Maintains | Outperform | |||
08/01/2023 | -51.08% | Stephens & Co. | $87 → $89 | Maintains | Equal-Weight | |||
08/01/2023 | -50.53% | Citigroup | $83 → $90 | Maintains | Buy | |||
07/11/2023 | -48.33% | Mizuho | $81 → $94 | Maintains | Buy | |||
06/20/2023 | -49.43% | Truist Securities | $84 → $92 | Maintains | Buy | |||
06/14/2023 | -47.78% | Jefferies | → $95 | Reiterates | → Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Tenet Healthcare (THC)?
El último precio objetivo de Tenet Healthcare (NYSE:THC) fue comunicado por Wells Fargo el agosto 14, 2025. La firma de analistas fijó un precio objetivo para $200.00 que espera THC a rise dentro de 12 meses (un posible 9.93% upside). 43 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Tenet Healthcare (THC)?
La última calificación de analistas para Tenet Healthcare (NYSE:THC) fue proporcionada por Wells Fargo, y Tenet Healthcare mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Tenet Healthcare (THC)?
La última revisión al alza de Tenet Healthcare Corp se produjo en mayo 29, 2025, cuando Wells Fargo elevó su precio objetivo a $195. Wells Fargo anteriormente tenía an equal-weight para Tenet Healthcare Corp.
¿Cuándo fue la última revisión a la baja de Tenet Healthcare (THC)?
La última revisión a la baja de Tenet Healthcare Corp se produjo en julio 28, 2025, cuando Wolfe Research cambió su precio objetivo de N/A a N/A para Tenet Healthcare Corp.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Tenet Healthcare (THC)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Tenet Healthcare, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Tenet Healthcare se registró el agosto 14, 2025, por lo que la próxima calificación estará disponible en torno al agosto 14, 2026.
¿Es correcta la calificación de los analistas sobre Tenet Healthcare (THC)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Tenet Healthcare (THC) fue un mantuvo con un precio objetivo de $195.00 a $200.00. El precio actual al que cotiza Tenet Healthcare (THC) es de $181.94, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.